1 Matching Annotations
  1. Last 7 days
    1. A male patient in his 20s initially presented to the UOB at the NCI with several clinical phenotypic manifestations consistent with a diagnosis of VHL. At an outside institution, the patient had previously had multiple resections of CNS haemangioblastomas, a left robotic partial nephrectomy for multifocal ccRCC (five tumours ranging from 1.3 cm to 4.6 cm in largest dimension) and a right ablation of a central renal tumour. Previous germline mutation testing had been negative for VHL mutation and the patient reported no family history of kidney cancer or any other clinical manifestations consistent with VHL.Further evaluation and imaging at the UOB revealed that the patient had bilateral epididymal cysts, numerous pancreatic cysts and numerous bilateral renal cysts with two solid lesions in the left kidney (2.3 cm and 1.7 cm) and one solid lesion in the right kidney (2.1 cm) (figure 1A). Currently, the adrenal glands appear unaffected. These clinical manifestations were consistent with a diagnosis of VHL. Germline genetic analysis was repeated using DNA derived from peripheral blood leucocytes to evaluate for point mutations, insertions, deletions or duplications in VHL and was negative. To assess the possibility of mosaicism, germline genetic testing was additionally performed on DNA derived from saliva containing buccal epithelial cells and from fibroblasts acquired via a skin punch biopsy. No alterations of the VHL gene were detected.<img class="highwire-fragment fragment-image" alt="Figure 1" src="https://jmg.bmj.com/content/jmedgenet/59/1/18/F1.medium.gif" width="440" height="202"/>Download figure Open in new tab Download powerpoint Figure 1 Imaging and karyotype analysis of patient with von Hippel-Lindau (VHL) disease. (A) Coronal (upper) and axial (lower) MRI images of the abdomen of the patient with VHL showing multiple bilateral renal cysts (green arrows), one of the left-sided solid lesions (red arrows) and multiple pancreatic cysts (blue arrow). (B) Karyotype analysis of the germline DNA of the patient with VHL demonstrating a translocation between chromosomes 1 and 3.Germline translocations involving chromosome 3 have been reported and shown to result in an increased risk of kidney cancer, but to date no other VHL-associated clinical manifestations have been seen.13–16 To investigate whether a translocation could cause these clinical features, a karyotype analysis was performed. The patient was shown to have a germline translocation between chromosomes 1 and 3, 46, XY, t(1;3)(p36.3;p25). The predicted breakpoint at chromosome 3p25 was in the same region as the VHL gene, potentially directly disrupting the VHL gene (figure 1B).Paired-end WGS was performed on the DNA derived from peripheral blood leucocytes and several paired reads were found with one pair mate on chromosome 1 and the other within intron 2 of the VHL gene on chromosome 3. To confirm the breakpoints, primers were designed to amplify and Sanger sequence the breakpoint regions in both derivative chromosomes. The breakpoint on the derivative chromosome 3 had a 2 bp sequence present in both the wild-type sequences for chromosomes 1 and 3 with the last unique base of chromosome 1p at 716 702 bp (hg19) and the first unique base of chromosome 3p at 10 191 126 bp (hg19) (figure 2). The breakpoint on the derivative chromosome 1 had an insertion of 10 bp which was a duplication of an upstream region of chromosome 3, with the last unique base of chromosome 3p at 10,191,119 bp (hg19) and the first unique base of chromosome 1p at 716 698 bp (hg19) (figure 2). This results in a few base pairs being lost from wild-type sequence of chromosome 3 but no loss of sequence compared with wild-type chromosome 1. The break on chromosome 3p was confirmed to be within the second intron of the VHL gene creating a germline alteration that would result in either a truncated VHL protein or no protein being produced by this allele. However, the break on chromosome 1p did not occur within a gene, and the nearest telomeric gene, LOC100288069, was ~2.6 kb away and the nearest centromeric gene, FAM87B, was ~36 kb away. Neither of these genes were mutated in any of the 426 sporadic ccRCCs analysed by the Cancer Genome Atlas suggesting that alterations in either of these genes is unlikely to influence the risk of kidney cancer in this patient.

      PatientID: N/A (case)

      KindredID: 1

      Case: M, 20Y0M, Ethnicity Unknown

      DiseaseAssertion: VHL

      FamilyInfo: The patient reported no family history of kidney cancer or any other clinical manifestations related to VHL disease. Sincehe patient had no family history of VHL, the authors suggest that the germline translocation was a de novo event.

      CasePresentingHPOs: HP:0006880; HP:0030424; HP:0001737; HP:0000107; HP:0009726 (Cerebellar hemangioblastomas; Epididymal cysts; Pancreatic Cysts; Renal cysts; Renal Tumors)

      CaseHPOFreeText: The patient presented to the Urologic Oncology Branch at the National Cancer Institute with clinical manifestations consistent with VHL in his 20s (exact age of patient was not indicated). He had multiple cerebellar haemangioblastomas, bilateral epididymal cysts, pancreatic cysts, and bilateral renal tumours and cysts. Standard genetic testing for VHL did not detect a mutation. Karyotype analysis however revealed a translocation between chromosomes 1 and 3. This balanced translocation with a breakpoint within the second intro of the VHL gene was confirmed by whole genome sequencing.

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: N/A

      PreviouslyPublished: N/A

      SupplementalData: N/A

      Variant: t(1;3)(p36.3;p25)

      LegacyVariant: N/A

      CaseProblemVariantFreeText: N/A

      ClinVarID: N/A

      CAID: N/A

      gnomAD: N/A

      VariantEvidence: N/A

      MutationType: balanced_translocation

      CivicName: t(1;3)(p36.3;p25)

      MultipleGeneVariants: N/A